2. Search Result
Search Result
Results for "

Chronic myeloid leukaemia

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117664
    PNR-7-02

    		Reverse Transcriptase Inflammation/Immunology Cancer
    PNR-7-02 inhibits Pol η function with an IC50 value of near 8 μM, which binds to the little finger domain. PNR-7-02 is also an inhibitor against hRev1 and hpol lambda (λ). PNR-7-02 acts synergistically with Cisplatin (HY-17394) to kill chronic myeloid leukaemia and ovarian cancer cell lines. PNR-7-02 is an indole thio-barbituric acid (ITBA) derivative with both N-napthoyl moiety and 5-chloro substituent on the indole ring .
    PNR-7-02
  • HY-10226
    JNJ-16241199

    R306465

    		 Apoptosis HDAC Cancer
    JNJ-16241199 (R306465) is an orally active, selectivehydroxamate-based histone deacetylase (HDAC) inhibitor, with theIC50of 3.3 nM and 23 nM for HDAC1and HDAC8, respectively.JNJ-16241199induces histone 3 acetylation and strongly increases the expression of p21 waf1, cip1 in A2780 ovarian carcinoma cells.JNJ-16241199 inducescell apoptosisand shows anticancer activityin a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study .
    JNJ-16241199
  • HY-E70639
    ABL1 Q252H Recombinant Human Active Protein Kinase

    		Bcr-Abl Cancer
    The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 Q252H Recombinant Human Active Protein Kinase is a recombinant ABL1 Q252H protein that can be used to study ABL1 Q252H-related functions .
    ABL1 Q252H Recombinant Human Active Protein Kinase
  • HY-E70640
    ABL1 T315I Recombinant Human Active Protein Kinase

    		Bcr-Abl Cancer
    The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 T315I Recombinant Human Active Protein Kinase is a recombinant ABL1 T315I protein that can be used to study ABL1 T315I-related functions .
    ABL1 T315I Recombinant Human Active Protein Kinase
  • HY-E70638
    ABL1 M351T Recombinant Human Active Protein Kinase

    		Bcr-Abl Cancer
    The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 M351T Recombinant Human Active Protein Kinase is a recombinant ABL1 M351T protein that can be used to study ABL1 M351T-related functions .
    ABL1 M351T Recombinant Human Active Protein Kinase
  • HY-E70635
    ABL1 F317I Recombinant Human Active Protein Kinase

    		Bcr-Abl Cancer
    The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 F317I Recombinant Human Active Protein Kinase is a recombinant ABL1 F317I protein that can be used to study ABL1 F317I-related functions .
    ABL1 F317I Recombinant Human Active Protein Kinase
  • HY-E70641
    ABL1 Y253F Recombinant Human Active Protein Kinase

    		Bcr-Abl Cancer
    The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 Y253F Recombinant Human Active Protein Kinase is a recombinant ABL1 Y253F protein that can be used to study ABL1 Y253F-related functions .
    ABL1 Y253F Recombinant Human Active Protein Kinase
  • HY-E70636
    ABL1 G250E Recombinant Human Active Protein Kinase

    		Bcr-Abl Cancer
    The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 G250E Recombinant Human Active Protein Kinase is a recombinant ABL1 G250E protein that can be used to study ABL1 G250E-related functions .
    ABL1 G250E Recombinant Human Active Protein Kinase
  • HY-E70637
    ABL1 H396P Recombinant Human Active Protein Kinase

    		Bcr-Abl Cancer
    The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 H396P Recombinant Human Active Protein Kinase is a recombinant ABL1 H396P protein that can be used to study ABL1 H396P-related functions .
    ABL1 H396P Recombinant Human Active Protein Kinase
  • HY-E70634
    ABL1 E255K Recombinant Human Active Protein Kinase

    		Bcr-Abl Cancer
    The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 E255K Recombinant Human Active Protein Kinase is a recombinant ABL1 E255K protein that can be used to study ABL1 E255K-related functions .
    ABL1 E255K Recombinant Human Active Protein Kinase
  • HY-157327
    AKE-72

    		Bcr-Abl Cancer
    AKE-72 (compound 5) is a potent inhibitor of Pan-BCR-ABL. AKE-72 inhibits BCR-ABL WT, BCR-ABL T315, BCR-ABL E255K, BCR-ABL F3171, BCR-ABL H396P and BCR-ABL Q252H with IC50s of < 0.5, 9, 8.98, 3.12, < 1.0 and 3.88 nM, respectively. AKE-72 has anti-leukemic activity against K-562 cell line .
    AKE-72

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: